For as good as it is, I don't understand the Reuters article about the FDA staffers disapproval of it. Seemed more like a hit job by analyst/brokers trying to get their clients in cheap before Adcom. I missed this opportunity completely by holding, need 2.17 to break even. Will be more careful with these plays till I get my head around using options. I normally short theses kind of events.
News 
Market Data 
Discover 
